| Drug / Therapy | ZORYVE |
| Indication | ARQT PDUFA |
| Decision Type | PDUFA |
| Conditions | ARQT PDUFA |
| Interventions | ZORYVE |
Arcus Biosciences (ARQT) operates in the Immuno-Oncology sector. The current BiotechSign Score is 51 (Grade: C).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The PDUFA date for ZORYVE by Arcus Biosciences (ARQT) is scheduled for February 23, 2027. This is the target date for the FDA to make a decision on this application.
ZORYVE is being developed by Arcus Biosciences for the treatment of ARQT PDUFA. It is under FDA review.
If ZORYVE receives FDA approval, Arcus Biosciences (ARQT) would be able to market the drug in the United States for ARQT PDUFA. This typically leads to significant stock price movement for biotech companies. Investors should monitor the PDUFA date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for ARQT on DilutionWatch at dilutionwatch.com/stock/ARQT.html.
You can view the full BiotechSign company profile for Arcus Biosciences (ARQT) at biotechsign.com/app/company/ARQT, which includes the BiotechSign Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSign is not a registered investment advisor.